Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction

Atherosclerosis

Volumn 240, Issue 2, 2015, Pages 477-481

  Moreno Velásquez, Ilais ^a   Golabkesh, Zahra ^a   Källberg, Henrik ^a   Leander, Karin ^a   de Faire, Ulf ^a,b   Gigante, Bruna ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

Author keywords

Biomarkers; Interleukin 6 receptor; Myocardial infarction; SIL6R; Soluble gp130

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6 RECEPTOR; BIOLOGICAL MARKER; IL6R PROTEIN, HUMAN; IL6ST PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; SEX; SMOKING; AGED; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; IMMUNOLOGY; MYOCARDIAL INFARCTION; ODDS RATIO; PROGNOSIS; PROTECTION; RISK FACTOR; STATISTICAL MODEL; SWEDEN; UPREGULATION;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CYTOKINE RECEPTOR GP130; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PROGNOSIS; PROTECTIVE FACTORS; RECEPTORS, INTERLEUKIN-6; RISK FACTORS; SWEDEN; UP-REGULATION;

EID: 84928667962     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.04.014     Document Type: Article

References (40)

1. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001, 15(1):43-58.
2. Hartman J., Frishman W.H. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol. Rev. 2014, 22(3):147-151.
3. Boekholdt S.M., Stroes E.S. The interleukin-6 pathway and atherosclerosis. Lancet 2012, 379(9822):1176-1178.
4. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 2012, 8(9):1237-1247.
5. Schuett H., Oestreich R., Waetzig G.H., Annema W., Luchtefeld M., Hillmer A., et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32(2):281-290.
6. Bennet A.M., Prince J.A., Fei G.Z., Lyrenas L., Huang Y., Wiman B., et al. Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. Atherosclerosis 2003, 171(2):359-367.
7. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101(15):1767-1772.
8. Kanda T., Inoue M., Kotajima N., Fujimaki S., Hoshino Y., Kurabayashi M., et al. Circulating interleukin-6 and interleukin-6 receptors in patients with acute and recent myocardial infarction. Cardiology 2000, 93(3):191-196.
9. Anderson D.R., Poterucha J.T., Mikuls T.R., Duryee M.J., Garvin R.P., Klassen L.W., et al. IL-6 and its receptors in coronary artery disease and acute myocardial infarction. Cytokine 2013, 62(3):395-400.
10. Askevold E.T., Nymo S., Ueland T., Gravning J., Wergeland R., Kjekshus J., et al. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circ. Heart Fail. 2013, 6(1):91-98.
11. Gigante B., Vikstrom M., Meuzelaar L.S., Chernogubova E., Silveira A., Hooft F.V., et al. Variants in the coagulation factor 2 receptor (F2R) gene influence the risk of myocardial infarction in men through an interaction with interleukin 6 serum levels. Thromb. Haemost. 2009, 101(5):943-953.
12. Reuterwall C., Hallqvist J., Ahlbom A., De Faire U., Diderichsen F., Hogstedt C., et al. Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. The SHEEP Study Group. J.Intern. Med. 1999, 246(2):161-174.
13. Leander K., Gigante B., Silveira A., Vikstrom M., Hamsten A., Hogberg J.N.A.M.P.T. (visfatin) and AKT1 genetic variants associate with myocardial infarction. Clin. Chim. Acta 2012, 413(7-8):727-732.
14. Bennet A.M., Brismar K., Hallqvist J., Reuterwall C., De Faire U. The risk of myocardial infarction is enhanced by a synergistic interaction between serum insulin and smoking. Eur. J. Endocrinol. 2002, 147(5):641-647.
15. Rothman K. Epidemiology: An Introduction 2012, second ed.
16. Knol M.J., VanderWeele T.J., Groenwold R.H., Klungel O.H., Rovers M.M., Grobbee D.E. Estimating measures of interaction on an additive scale for preventive exposures. Eur. J. Epidemiol. 2011, 26(6):433-438.
17. Andersson T., Alfredsson L., Kallberg H., Zdravkovic S., Ahlbom A. Calculating measures of biological interaction. Eur. J. Epidemiol. 2005, 20(7):575-579.
18. Romano M., Sironi M., Toniatti C., Polentarutti N., Fruscella P., Ghezzi P., et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997, 6(3):315-325.
19. Taleb S., Tedgui A., Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J.Intern. Med. 2008, 263(5):489-499.
20. Protogerou A.D., Zampeli E., Fragiadaki K., Stamatelopoulos K., Papamichael C., Sfikakis P.P. Apilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 2011, 219(2):734-736.
21. Ritschel V.N., Seljeflot I., Arnesen H., Halvorsen S., Weiss T., Eritsland J., et al. IL-6 signalling in patients with acute ST-elevation myocardial infarction. Res. Immunol. 2014, 4:8-13.
22. Fiskesund R., Su J., Bulatovic I., Vikstrom M., de Faire U., Frostegard J. IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL. Res. Immunol. 2012, 2:13-18.
23. Gigante B., Leander K., Vikstrom M., Baldassarre D., Veglia F., Strawbridge R.J., et al. Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men. Atherosclerosis 2014, 236(2):394-399.
24. Rose-John S., Scheller J., Elson G., Jones S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J.Leukoc. Biol. 2006, 80(2):227-236.
25. Yamamoto K., Rose-John S. Therapeutic blockade of interleukin-6 in chronic inflammatory disease. Clin. Pharmacol. Ther. 2012, 91(4):574-576.
26. Scheller J., Rose-John S. The interleukin 6 pathway and atherosclerosis. Lancet 2012, 380(9839):338.
27. Schuett H., Luchtefeld M., Grothusen C., Grote K., Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb. Haemost. 2009, 102(2):215-222.
28. Doran A.C., Meller N., McNamara C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28(5):812-819.
29. Scheller J., Garbers C., Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin. Immunol. 2013.
30. Kallberg H., Ding B., Padyukov L., Bengtsson C., Ronnelid J., Klareskog L., et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann. Rheum. Dis. 2011, 70(3):508-511.
31. Leander K., Wiman B., Hallqvist J., Falk G., De Faire U. The G-455A polymorphism of the fibrinogen Bbeta-gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women. J.Intern. Med. 2002, 252(4):332-341.
32. Gigante B., Leander K., Vikstrom M., Ye S., de Faire U. Chromosome 1p13 genetic variants antagonize the risk of myocardial infarction associated with high ApoB serum levels. BMC Cardiovasc. Disord. 2012, 12:90.
33. Gigante B., Bennet A.M., Leander K., Vikstrom M., de Faire U. The interaction between coagulation factor 2 receptor and interleukin 6 haplotypes increases the risk of myocardial infarction in men. PLoS One 2010, 5(6):e11300.
34. Mahdi H., Fisher B.A., Kallberg H., Plant D., Malmstrom V., Ronnelid J., et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat. Genet. 2009, 41(12):1319-1324.
35. Knol M.J., VanderWeele T.J. Recommendations for presenting analyses of effect modification and interaction. Int. J. Epidemiol. 2012, 41(2):514-520.
36. Zuliani G., Galvani M., Maggio M., Volpato S., Bandinelli S., Corsi A.M., et al. Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance. Atherosclerosis 2010, 213(1):319-324.
37. Hamsten A., Wiman B., de Faire U., Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N.Engl. J. Med. 1985, 313(25):1557-1563.
38. Hamsten A., Walldius G., Dahlen G., Johansson B., De Faire U. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis 1986, 59(2):223-235.
39. Ueda K., Takahashi M., Ozawa K., Kinoshita M. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction. Am. Heart J. 1999, 138(5 Pt 1):908-915.
40. Morris T., Stables M., Hobbs A., de Souza P., Colville-Nash P., Warner T., et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J.Immunol. 2009, 183(3):2089-2096.